Fibrocell Science Revenue and Competitors
Estimated Revenue & Valuation
- Fibrocell Science's estimated annual revenue is currently $2.6M per year.
- Fibrocell Science's estimated revenue per employee is $155,000
Employee Data
- Fibrocell Science has 17 Employees.
- Fibrocell Science grew their employee count by 6% last year.
Fibrocell Science's People
Name | Title | Email/Phone |
---|
Fibrocell Science Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | $0.9M | 6 | -14% | N/A | N/A |
#4 | $1.1M | 7 | 0% | N/A | N/A |
#5 | $10.9M | 70 | 3% | N/A | N/A |
#6 | $0.7M | 9 | 29% | N/A | N/A |
#7 | $4M | 26 | -16% | N/A | N/A |
#8 | $1.7M | 11 | 22% | N/A | N/A |
#9 | $7.6M | 49 | 2% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Fibrocell Science?
Fibrocell is a cell and gene therapy company focused on improving the lives of people with rare diseases of the skin and connective tissue. The Company is utilizing its proprietary autologous fibroblast technology to develop personalized biologics that target the underlying cause of disease. Fibrocell’s pipeline of localized gene therapy candidates include FCX-007 for the treatment of RDEB, a life-threatening genetic disorder diagnosed in infancy with no cure or treatment approved by the U. S. Food and Drug Administration. Fibrocell is also developing FCX-013 for the treatment of moderate to severe localized scleroderma. For more information, visit www.fibrocell.com or follow Fibrocell on Twitter at @Fibrocell.
keywords:N/AN/A
Total Funding
17
Number of Employees
$2.6M
Revenue (est)
6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $1.5M | 17 | -6% | N/A |
#2 | $1.6M | 18 | 6% | N/A |
#3 | $1.6M | 18 | 13% | N/A |
#4 | $1.6M | 18 | -5% | N/A |
#5 | $2.8M | 18 | 6% | N/A |